The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Saphnelo (anifrolumab) is a medicine used to treat systemic lupus erythematosus (SLE). Lupus is a long-term autoimmune condition in which the immune system attacks the body’s healthy tissues. Saphnelo ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

WILMINGTON, Del.--(BUSINESS WIRE)--New subgroup analyses from the TULIP Phase III clinical trial program showed SAPHNELO (anifrolumab), a first-in-class type I interferon antagonist, in addition to ...

Saphnelo, a human monoclonal antibody, is a type 1 interferon (INF) receptor antagonist that inhibits a key protein in the immune system called the IFNAR receptor. This protein acts like a transmitter ...

AstraZeneca has received approval from the US Food and Drug Administration (FDA) for the subcutaneous self-administration of Saphnelo (anifrolumab-fnia) using the Saphnelo Pen autoinjector for ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved AstraZeneca’s anifrolumab-fnia, a first-in-class type I interferon receptor antagonist, for ...

WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 27, 2026-- AstraZeneca ’s SAPHNELO ® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen, for ...

The TULIP-SC trial evaluated the efficacy and safety of the subcutaneous administration of SAPHNELO compared to placebo in participants with moderately to severely active, autoantibody-positive SLE, ...

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. First-in-class SAPHNELO Pen now offers greater ...